Breast cancer survivors face a roughly 25 percent higher risk of developing a new, independent lung cancer compared to women who never had breast cancer. That elevated risk is not immediate; it builds over years and is shaped by the type of breast cancer treatment received, smoking history, and even the hormone-receptor profile of the original tumor. For many survivors, the surprise is learning that a spot found on a chest scan may not be metastatic breast cancer at all but an entirely separate malignancy, and the distinction between those two possibilities changes nearly everything about treatment and prognosis.
How Much Higher Is the Risk, and When Does It Appear?
A large meta-analysis pooling data from over a million breast cancer patients found that female breast cancer survivors had a significantly higher chance of developing a subsequent lung cancer, with a standardized incidence ratio of about 1.25.1PubMed. Risk and Influencing Factors for Subsequent Primary Lung Cancer After Treatment of Breast Cancer: A Systematic Review and Two Meta-Analyses Based on Four Million Cases A separate study using a time-updated analysis found a similar increase, with an adjusted hazard ratio of 1.24 after accounting for age, race, smoking patterns, and other factors.2BJC Reports. Assessing the risk of second primary lung cancer in women after previous breast cancer
Timing matters. In the first year after a breast cancer diagnosis, lung cancer risk does not appear to be higher than in the general population. But between one and nine years out, the risk begins to climb, and after ten or more years, it increases substantially, with one analysis showing a standardized incidence ratio of 1.68 in that later window.3PubMed Central. Primary Lung Cancer After Treatment for Breast Cancer This delayed pattern strongly suggests that the cancer treatments themselves, particularly radiation, contribute to the risk rather than some shared genetic predisposition acting on both cancers simultaneously.
The Role of Radiation Therapy
Radiation therapy is one of the most effective tools for reducing breast cancer recurrence, but the lung sits directly behind and beside the breast, making it impossible to avoid some incidental radiation exposure to lung tissue. The clinical question has always been whether that exposure is large enough to matter. The evidence says it is, but only on the side that was treated, and only after years have passed.
A study using national cancer registry data found that the risk of developing a new lung cancer on the same side as the radiated breast was elevated starting five to nine years after treatment, with the hazard growing over time. After more than 15 years, the risk on the treated side was about 30 percent higher than in women who did not receive radiation. The opposite lung showed no increase at any time point.4PubMed Central. Risk of developing subsequent primary lung cancer after receiving radiation for breast cancer That one-sided pattern is strong evidence that the radiation itself, not some systemic factor, is driving the excess risk.
A large national cohort study put a finer point on the dose-response relationship: for patients diagnosed with a second lung cancer five or more years after breast cancer treatment, the rate of lung cancer rose linearly by about 8.5 percent per gray of radiation delivered to the lung.5Radiotherapy and Oncology. Risk of second primary lung cancer after postoperative radiotherapy for breast cancer: A population-based cohort study A gray is a unit of absorbed radiation dose, and typical breast radiation plans deliver a few grays to portions of the nearby lung. So the absolute risk increase for any individual patient is modest, but it is real and it is cumulative over time.
How Modern Radiation Techniques Reduce Lung Exposure
The radiation techniques studied in many of the long-term risk analyses are older methods that exposed more lung tissue than today’s approaches do. Newer planning strategies aim to shrink the volume of lung that sits in the radiation field, and one of the most widely adopted is a technique called deep inspiration breath-hold. During treatment, you take a deep breath and hold it. Your lungs expand, which pushes the heart away from the chest wall on the left side and also changes the geometry so that less lung tissue ends up in the treatment beam. Studies comparing breath-hold with normal breathing have found meaningful dose reductions to the lungs, the heart, the esophagus, and the spinal cord.6PubMed Central. Dosimetric comparison of DIBH and FB for left-sided breast cancer radiation therapy The breath-hold approach specifically reduces the volume of lung exposed and lowers the average dose to lung tissue.7PubMed. Dosimetric and radiobiological advantages from deep inspiration breath-hold and free breath technique for left-sided breast radiation using 3DCRT, IMRT and Rapid Arc methods-a complete assessment
Different radiation delivery methods also distribute dose differently. A dosimetric comparison found that traditional three-dimensional conformal radiation therapy tends to deliver higher doses to the lung on the treated side, while newer rotational techniques like helical tomotherapy spread lower-level dose more broadly, raising estimated risk to the opposite lung and the contralateral breast instead.8PubMed Central. Dosimetric and Secondary Cancer Risk Comparison after Radiation Therapy for Breast Cancer with Three-Dimensional Conformal Radiotherapy, and Helical Tomotherapy Neither approach is universally better; the best plan depends on your anatomy and the location of the tumor. The point is that radiation oncologists now have tools to optimize the tradeoffs, and the doses reaching the lung are generally lower than they were a generation ago.
Smoking Multiplies Radiation Risk
If radiation is the match, smoking is the gasoline. The same dose-response study that quantified the per-gray increase in lung cancer found that the excess rate roughly doubled for people who had ever smoked: 17.3 percent per gray, compared with 8.5 percent per gray overall.5Radiotherapy and Oncology. Risk of second primary lung cancer after postoperative radiotherapy for breast cancer: A population-based cohort study Research on atomic-bomb survivors has shown a similar pattern: the combined effect of radiation and smoking on lung cancer was more than you would expect from simply adding the two risks together, at least among light to moderate smokers.9PubMed Central. Radiation and smoking effects on lung cancer incidence among atomic-bomb survivors
This is arguably the single most actionable piece of information in the entire topic. Breast cancer survivors who smoke, or who quit recently, carry a compounded risk that neither radiation nor smoking alone would produce. A pilot study of breast cancer survivors who smoked found that most current smokers in the sample were light smokers, averaging ten or fewer cigarettes a day, and more than half had attempted to quit in the past year.10PubMed Central. Cigarette smoking after surviving breast cancer: A pilot study That tells us many survivors already want to quit but may need more support. Oncology teams that actively address smoking cessation after a breast cancer diagnosis are doing lung cancer prevention at the same time.
Estrogen Receptor Status and Antiestrogen Therapy
Not all breast cancers carry the same downstream lung cancer risk. The hormone-receptor status of the original tumor turns out to be relevant. A study using U.S. cancer registry data found that women whose breast cancers were estrogen receptor-negative had a significantly elevated rate of second lung cancers, with a standardized incidence ratio of 1.20, while women with estrogen receptor-positive tumors showed no significant increase.11PubMed Central. The risk of a second primary lung cancer after a first invasive breast cancer according to estrogen receptor status The adjusted relative risk of lung cancer following ER-negative versus ER-positive breast cancer was 1.22.
One likely explanation involves treatment. Women with ER-positive breast cancers typically receive years of antiestrogen therapy such as tamoxifen or aromatase inhibitors. These drugs block estrogen signaling, and there is growing evidence that estrogen plays a role in lung tumor development too. Preclinical research has shown that antiestrogens and estrogen-synthesis inhibitors can slow lung tumor growth and even prevent lung tumors from forming in laboratory models.12PubMed Central. Targeting the estrogen pathway for the treatment and prevention of lung cancer Clinical data supports this: a population-based study found that antiestrogen use in breast cancer patients aged 50 and older was associated with a roughly 27 percent reduction in the risk of subsequent lung cancer compared to breast cancer survivors who did not receive antiestrogens.13PubMed. Antiestrogen use in breast cancer patients reduces the risk of subsequent lung cancer: A population-based study
A large Swedish study found that the lung cancer hazard was elevated regardless of whether women had received endocrine therapy or not, when comparing breast cancer survivors to women without breast cancer. The hazard ratios were nearly identical in both groups, around 1.33 to 1.35.14npj Breast Cancer. Risk of primary lung cancer after adjuvant radiotherapy in breast cancer—a large population-based study This suggests that while antiestrogen therapy may help, it does not fully erase the elevated risk. Other factors, including the radiation exposure itself, continue to contribute.
Telling a New Lung Cancer Apart from Metastatic Breast Cancer
When a breast cancer survivor develops a lung nodule, the first clinical question is whether the spot is a brand-new lung cancer or a metastasis from the original breast cancer. The answer is not academic. A new primary lung cancer can often be cured with surgery. A breast cancer metastasis to the lung is treated with systemic therapy, because surgery alone will not address disease that has already spread. Getting the diagnosis wrong in either direction can lead to the wrong treatment plan entirely.
Imaging offers some clues. PET-CT scans, which measure how actively a lesion takes up sugar, found that breast cancer metastases tended to have higher metabolic activity than new primary lung cancers. In one study of 120 breast cancer patients with a solitary lung nodule, the average metabolic uptake was substantially higher in the metastasis group than in the primary lung cancer group.15PubMed Central. Predicting solitary pulmonary lesions in breast cancer patients using 18 fluorodeoxyglucose-positron emission tomography/computed tomography combined with clinicopathological characteristics However, PET scans have limitations with small nodules. For nodules under 8 millimeters, one study found that PET sensitivity was just 17 percent, meaning most tiny metastases were missed, while specificity was 100 percent, meaning a positive result was reliable. For nodules 8 millimeters and larger, sensitivity improved to 77 percent.16PubMed. Indeterminate pulmonary nodules on CT images in breast cancer patient: the additional value of 18F-FDG PET/CT
When imaging is ambiguous, genomic profiling of biopsy tissue can settle the question. A study that compared the gene-mutation profiles of lung tumors with patients’ prior cancers found that the mutation fingerprint clearly distinguished primary lung cancers from metastases in all 24 patients studied. Strikingly, half of the genomic diagnoses disagreed with what pathologists had initially concluded using traditional methods alone.17PubMed Central. Discrimination Between Primary Lung Cancer and Lung Metastases by Genomic Profiling That 50 percent discordance rate is remarkable and argues strongly that genomic testing should be part of the workup when the diagnosis is unclear.
Surgical Outcomes for Second Primary Lung Cancer
There is a reasonable concern that a person who has already been treated for breast cancer might tolerate lung cancer surgery poorly or have worse outcomes. The evidence is reassuring. A study comparing patients who had surgery for a second primary lung cancer after a previous non-lung malignancy with patients undergoing first-time lung cancer surgery found no significant difference in five-year overall survival or disease-free survival between the two groups. Patients whose earlier cancer was breast or thyroid cancer fared even better than those whose prior malignancy was at other sites.18PubMed. Surgical outcomes of second primary lung cancer after the extrapulmonary malignancy The five-year overall survival for the second primary lung cancer group was about 73 percent, compared to roughly 82 percent in the first-time lung cancer group, a gap that was not statistically significant.
This is good news for breast cancer survivors facing a lung cancer diagnosis. Prior breast cancer treatment, including its physical toll, does not appear to compromise the ability to undergo curative lung surgery or to benefit from it. The key, of course, is catching the lung cancer early enough for surgery to be an option.
Shared Genetic Susceptibility
Beyond treatment-related risk, there may be shared genetic vulnerabilities that predispose some people to both cancers. A meta-analysis focused on the South Asian population found that a specific variant in the TP53 gene, which plays a central role in suppressing tumor growth throughout the body, was associated with increased risk of both breast cancer and lung cancer.19PubMed Central. Association of TP53 Codon 72 Arg>Pro Polymorphism with Breast and Lung Cancer Risk in the South Asian Population: A Meta-Analysis TP53 is one of the most commonly mutated genes across all human cancers, so finding overlap is not surprising, but it does raise the question of whether certain individuals carry an inherently higher baseline risk for both diseases, independent of what treatment they receive for the first one.
This genetic angle is still being explored. For most breast cancer survivors, treatment-related factors like radiation dose and smoking status are far more influential than inherited risk when it comes to developing a second lung cancer. But for families with strong histories of multiple cancer types, genetic counseling may help clarify whether underlying susceptibility genes are in play.
Screening and the Role of Low-Dose CT
Current lung cancer screening guidelines in the United States generally recommend annual low-dose CT for adults aged 50 to 80 who have a significant smoking history. Breast cancer survivorship alone is not currently an independent indication for screening. Whether it should be remains an open question. The elevated risk documented in the studies above, particularly for women who received radiation and who smoked, may warrant a lower threshold for screening referral in clinical practice.
One incidental benefit of low-dose chest CT is that it can detect breast density. A study of patients undergoing lung cancer screening found that CT-assessed breast density agreed with mammographic density in 87 percent of cases, suggesting that lung screening scans could serve double duty in alerting women to high breast density, a known risk factor for breast cancer.20Mary Ann Liebert, Inc., publishers. Low-Dose Chest CT-Participating in the Rise of Breast Density Awareness While this does not directly address second lung cancer risk, it illustrates how cross-screening incidental findings could benefit breast cancer survivors who are already getting chest imaging for other reasons.
HER2-Targeted Therapy Across Both Cancers
A small but growing intersection between breast and lung cancer treatment involves the HER2 protein. HER2 overexpression is well known in breast cancer, where it drives tumor growth and is the target of drugs like trastuzumab. A subset of non-small-cell lung cancers also carry HER2 mutations, and antibody-drug conjugates originally developed for breast cancer are now being tested and approved for lung cancer. The DESTINY-Lung02 trial evaluated trastuzumab deruxtecan in patients with HER2-mutant metastatic lung cancer and found clinical activity, though the treatment carried a risk of drug-related interstitial lung disease. Among patients in the 5.4 mg/kg arm who had previously received immunotherapy, about 15 percent developed this lung complication.21PubMed Central. Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial
For a breast cancer survivor who later develops a HER2-mutant lung cancer, this therapeutic overlap is relevant. A drug they may already be familiar with from breast cancer treatment could become part of their lung cancer regimen. At the same time, the interstitial lung disease risk means that prior chest radiation, which may have already sensitized lung tissue, becomes an important clinical consideration when choosing these therapies.
The Psychological Burden of a Lung Finding
Finding a pulmonary nodule in someone who has already survived one cancer is psychologically different from finding it in someone with no cancer history. For the survivor, every scan result carries the weight of possible recurrence or a new diagnosis. Research on patients undergoing lung cancer screening who had nodules detected found that at the time of detection, about 40 percent reported clinically significant anxiety and roughly 32 percent reported depression.22Translational Lung Cancer Research. Psychological distress in patients with detected pulmonary nodules from lung cancer screening Those are high numbers, and they likely underestimate the experience of breast cancer survivors for whom the finding activates memories of a prior cancer journey.
Interestingly, the same study found that patients who underwent surgical resection of their nodules experienced substantial psychological improvement compared to those placed on surveillance, suggesting that diagnostic uncertainty is itself a major driver of distress. For breast cancer survivors, this reinforces the value of prompt workup when a lung nodule is found. Months of watchful waiting may be medically appropriate for a tiny nodule, but the emotional cost should be acknowledged and addressed, ideally with access to psychosocial support services that many cancer centers now offer.